Profarm sees EU drug-supply antitrust complaint against Amgen rejected
( June 19, 2026, 11:55 GMT | Official Statement) -- MLex Summary: The European Commission has rejected a complaint from Greek pharmaceutical wholesaler Profarm against medication producer Amgen, according to a decision published on Friday. The complainant was arguing that Amgen refused to supply it and other companies active in “low-price” member states. But the regulator said that there was only a "limited likelihood of establishing the existence of an infringement." It also said that Profarm had no "legitimate interest" in the complaint regarding other companies in similar positions.Decision is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.